Team:Toronto/Trial

From 2012.igem.org

Revision as of 23:02, 22 August 2012 by Moustafa (Talk | contribs)

Banner

May 2012

Click on a highlighted day to view the notebook items for that day.

  • SU | MO | TU | WE | TH | FR | SA

June 2012

Click on a highlighted day to view the notebook items for that day.

  • SU | MO | TU | WE | TH | FR | SA

July 2012

Click on a highlighted day to view the notebook items for that day.

August 2012

Click on a highlighted day to view the notebook items for that day.

September 2012

Click on a highlighted day to view the notebook items for that day.



  May 17

  • 16 plates each of LB agar, ampicillin, tetracycline, and chloramphenicol were made.
  • To test the effectiveness of our antibiotic stock, five vials were created, and were kept in the shaker.
  • Vial one contained LB control; vial two contained LB and DH5α; vial three contained LB, DH5α, and ampicillin; vial four contained LB, DH5α, and chloramphenicol; vial five contained LB, DH5α, and tetracycline.


 May 18

  • Placed all the agar plates in the fridge, as no contamination was visible. Vial two was cloudy, as expected, indicating DH5α growth. The large block of ice formed over ten years' neglect in the 4°C fridge below our lab bench was cleaned with a chisel and mallet.
  • Four plates were prepared with DH5α: LB agar; LB ampicillin plate; LB tetracycline plate; LB chloramphenicol plate.
  • Vial Two was disposed of after bleaching. Stocks of 70% and 100% EtOH were obtained free from the Bendeck lab upstairs, replenishing our meagre stock.


  May 22

  • Made 1L of LB, as well as autoclaved some glassware. Only plate one from May 18 showed any bacterial growth after incubation at 4°C overnight, indicating good sterile technique during the training exercises yesterday.
  • SNC Lavalin, Monsanto, and New England BioLabs were contacted for funding enquiries. Approached Rob Reedijk about consolidation of financial accounts. Obtained A. thaliana seed from the McCourt lab at EEB, along with their recommended growth protocol.


  May 23

  • For demonstration purposes, we transformed cyan fluorescent protein from the BioBrick distribution plates with ampicillin resistance into DH5αC (competent DH5α).


  May 24

  • Checked the cyan fluorescent transformation, which failed. To check whether the BioBrick plasmids were compromised, or whether our technique was to blame, we will retry the transformation with another BioBrick. Ordered supplies from MedStore.


  May 25

  • Made kanamycin plates, and checked on the May 24 transformations, which proved to be successful. Aimed to finalise the phytase construct.


  May 28

  • Various sponsorship opportunities were pursued for the lab for much of the day.
  • 2 test transformations were performed as another tutorial. Kanamycin's efficiency was tested with the following three treatments: LB; LB and DH5αC; LB, DH5αC, and K.


  May 29

  • Tested a 2µL/mL kanamycin overnight culture versus an LB blank on the spectrophotometer. Placed two different projects into the shaker: Project One (10mL LB; 10µL C; 20µL DH5α): LB control; LB, DH5α, and C; LB, DH5α, C, and BioBrick K414007. Project Two (10mL LB; 20µL DH5α): LB control; LB and DH5α; LB, DH5α, and 20µL K; LB, DH5α, and 25µL K; LB, DH5α, and 30µL K.


  May 30

  • The LB controls failed from yesterday, so the 500mL container of LB from which we took yesterday's samples was thrown out. The K414007 promoter was miniprepped using a Qiagen Plasmid Extraction Kit. Using the nanodrop, we found our extraction sample to have a density of 20ng/µL – good miniprep. Performed a transformation using K414007, so as to keep plates in the fridge with this part handy.
UofT Logo
Banner